Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan;5(1):27-32.
doi: 10.4103/0976-500X.124416.

Diethylentriaminepenta acetic acid glucose conjugates as a cell permeable iron chelator

Mona Mosayebnia  1 , Mehdi Shafiee-Ardestani  2 , Parvin Pasalar  3 , Mojgan Mashayekhi  1 , Massoud Amanlou  1
Affiliations

Diethylentriaminepenta acetic acid glucose conjugates as a cell permeable iron chelator

Mona Mosayebnia et al. J Pharmacol Pharmacother. 2014 Jan.

Abstract

Objective: To find out whether DTPA-DG complex can enhance clearance of intracellular free iron.

Materials and methods: Diethylenetriaminepentaacetic acid-D-deoxy-glucosamine (DTPA-DG) was synthesized and examined for its activity as a cell-permeable iron chelator in human hepatocellular carcinoma (HEPG2) cell line exposed to high concentration of iron sulfate and compared with deferoxamine (DFO), a prototype iron chelator. The effect of DTPA-DG on cell viability was monitored using the 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide MTT assay as well.

Results: There was a significant increase of iron level after iron overload induction in HEPG2 cell culture. DTPA-DG presented a remarkable capacity to iron burden reducing with estimated 50% inhibitory concentration value of 65.77 nM. In fact, glycosyl moiety was gained access of DTPA to intracellular iron deposits through glucose transporter systems.

Conclusion: DTPA-DG, more potent than DFO to sequester deposits of free iron with no profound toxic effect. The results suggest the potential of DTPA-DG in chelating iron and permitting its excretion from primary organ storage.

Keywords: Cell-permeable; glycosyl moiety; human hepatocellular carcinoma; iron chelation; iron overload.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Structural formula of Puchel, lipophilic derivative of diethylenetriaminepentaacetic acid used for plutonium decorporation
Figure 2
Figure 2
Diethylenetriaminepentaacetic acid-folate structure, conjugated form of DTPA for tumor targeting-delivery
Figure 3
Figure 3
Chemical structure of diethylenetriaminepentaacetic acid-D-deoxy-glucosamine
Figure 4
Figure 4
Cellular iron level in control and iron-overload human hepatocellular carcinoma cell model as measurement by atomic absorption spectrometry. Measurements were performed with sample triplicates (n = 3)
Figure 5
Figure 5
MTT assay of cytotoxicity associated with various concentrations of diethylenetriaminepentaacetic acid-D-deoxy-glucosamine after 48 h. Data are presented as the percentage of cell viability relative to the untreated normal human hepatocellular carcinoma (mean ± standard deviation, n = 3). As a result, a negligible (P > 0.05) decrease of cell viability observed by MTT test
Figure 6
Figure 6
A dose-dependent decrease of free iron content after 24 h incubation of human hepatocellular carcinoma cells at 37°C which treated with 20-100 nM of diethylenetriaminepentaacetic acid-D-deoxy-glucosamine. The decrease was significant (P < 0.05) at concentration equal to or higher than 40 nM of DTPA-DG in comparison with untreated cells (n = 3). Results are the mean ± standard deviation of three separate experiments
Figure 7
Figure 7
The comparison of two chelators diethylenetriaminepentaacetic acid-D-deoxy-glucosamine and deferoxamine efficacy in similar conditions after 24 h indicated statistically (P < 0.05) a higher reducing of cellular iron content with DTPA-DG than with DFO at much lower doses. Results are the mean ± standard deviation of three separate experiments (n = 3)
Figure 8
Figure 8
A significant (P < 0.05, r2 = 0.994) correlation with iron chelator dose and its success in reducing cellular iron content is shown in this figure. Diethylenetriaminepentaacetic acid D-deoxy-glucosamine at concentration of 65.77 nM has been able to reduce 50% of iron deposits
See this image and copyright information in PMC

References

    1. Felitti VJ. Hemochromatosis: A common, rarely diagnosed disease. Perm J. 1999;3:10–22.
    1. Merryweather-Clarke AT, Pointon JJ, Jouanolle AM, Rochette J, Robson KJ. Geography of HFE C282Y and H63D mutations. Genet Test. 2000;4:183–98. - PubMed
    1. Ryan E, O’keane C, Crowe J. Hemochromatosis in Ireland and HFE. Blood Cells Mol Dis. 1998;24:428–32. - PubMed
    1. Brissot P. Diagnosis and current treatments for primary iron overload. Am J Hematol. 2007;82:1140–1. - PubMed
    1. Payne KA, Rofail D, Baladi JF, Viala M, Abetz L, Desrosiers MP, et al. Iron chelation therapy: Clinical effectiveness, economic burden and quality of life in patients with iron overload. Adv Ther. 2008;25:725–42. - PubMed

LinkOut - more resources